公开(公告)号：US10809258B2

公开(公告)日：2020-10-20

申请号：US15042695

申请日：2016-02-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ewelina Hegel ,  Georg Kurz ,  Eloisa Lopez-Calle ,  Josef Roedl

IPC: G01N33/48 ,  G01N33/557 ,  G01N33/53

Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.

公开(公告)号：US20190388402A1

公开(公告)日：2019-12-26

申请号：US16562629

申请日：2019-09-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ewelina Hegel ,  Hans-Peter Josel ,  Eloisa Lopez-Calle ,  Josef Roedl ,  Noah Weiss ,  Benjamin Tiemann

IPC: A61K31/436 ,  A61K47/18 ,  A61K9/08

Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.

公开(公告)号：US20160161480A1

公开(公告)日：2016-06-09

申请号：US15042695

申请日：2016-02-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ewelina Hegel ,  Georg Kurz ,  Eloisa Lopez-Calle ,  Josef Roedl

IPC: G01N33/557

Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.

Abstract translation: 用于测定样品中特定分析物的量的方法，其可以通过光度测定显示前区效应，其中所述特异性分析物在分析物与分析物特异性相互作用之后的反应混合物的光学信号的变化中定量 测定试剂。 同时测量样品中用于测定分析物的波长下确定的特定分析物的光学信号，并至少在用于在完整反应时间内检测前区效应的附加特定波长。 通过使用在用于检测前区效应的波长处获得的信号来计算反应速率比R. 通过比较计算的比值R与预定的极限值，判断样品中是否存在前区效应。

公开(公告)号：US20150044780A1

公开(公告)日：2015-02-12

申请号：US14524700

申请日：2014-10-27

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Georg Kurz ,  Eloisa Lopez-Calle

IPC: G01N33/543 ,  G06F19/00 ,  G01D18/00

CPC classification number: G01N33/54393 ,  G01D18/00 ,  G01N21/274 ,  G01N21/63 ,  G01N21/78 ,  G01N21/82 ,  G01N33/52 ,  G01N33/54313 ,  G01N33/54346 ,  G01N33/573 ,  G01N33/6827 ,  G01N33/92 ,  G01N2021/825 ,  G06F19/18 ,  G16H50/30

Abstract: A method for determining the amount of specific analyte of a sample which may show interferences by photometric assays, wherein the analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific reagents. Multiple calibration curves are generated for multiple wavelengths for the specific analyte. An interference test is performed simultaneously to the determination of the specific analyte, for quantifying the amount of interfering substances present in the sample. The amount of each interfering substances is compared to predetermined cut-off values. The optical signal for the specific analyte is measured in the reaction mixture at multiple wavelengths over the complete reaction time, and a calibration curve is selected depending on the interfering substances. The amount of specific analyte is quantified by comparison with the selected calibration curve for the chosen wavelengths.

Abstract translation: 用于通过光度测定法确定可能显示干扰的样品的特定分析物的量的方法，其中在分析物与分析物特异性试剂的相互作用之后，根据反应混合物的光学信号的变化量化分析物。 为特定分析物的多个波长产生多个校准曲线。 对确定特定分析物同时进行干扰测试，以量化样品中存在的干扰物质的量。 将每个干扰物质的量与预定的截止值进行比较。 在整个反应时间内，在反应混合物中以多个波长测量特定分析物的光学信号，并根据干扰物质选择校准曲线。 通过与所选择的波长的所选校准曲线进行比较来量化特定分析物的量。

公开(公告)号：US10288609B2

公开(公告)日：2019-05-14

申请号：US15951536

申请日：2018-04-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Thorsten Brueckner ,  Eloisa Lopez-Calle ,  Norbert Oranth ,  Josef Roedl

IPC: G01N21/27 ,  G01N21/63 ,  G01N33/52 ,  G06F19/18 ,  G01N33/543 ,  G16B20/00 ,  G01N21/78 ,  G01N21/82 ,  G01D18/00 ,  G01N33/573 ,  G01N33/68 ,  G01N33/92 ,  G16H50/30

Abstract: A method for determining the amount of a specific analyte by photometric assays, wherein the specific analyte in a sample reacts with an analyte specific reaction partner in a reaction mixture. At least two calibration curves are generated, the first calibration curve recorded at a first wavelength is optimized for low concentrations of the specific analyte thereby maximizing the lower detection limit and, the second calibration curve recorded at a second wavelength is optimized for high concentrations of the specific analyte thereby maximizing the upper detection limit. The optimized lower detection limit and the optimized upper detection limit results in an extended dynamic range.

公开(公告)号：US20180264471A1

公开(公告)日：2018-09-20

申请号：US15982009

申请日：2018-05-17

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christoph Boehm ,  Thorsten Brueckner ,  Thomas Fischer ,  Eloisa Lopez-Calle ,  Sascha Lutz ,  Josef Roedl ,  Juergen Spinke ,  Pamela Espindola ,  Thomas Manuel Keller ,  Thomas Dolbinow ,  Sabrina Adler ,  Erik Beiersdorf ,  Domenik Wensorra

IPC: B01L3/00

CPC classification number: B01L3/502753 ,  B01L3/5023 ,  B01L3/502715 ,  B01L3/50273 ,  B01L3/502738 ,  B01L2200/0605 ,  B01L2200/16 ,  B01L2300/0627 ,  B01L2300/0803 ,  B01L2300/0864 ,  B01L2300/0867 ,  B01L2300/087 ,  B01L2400/0406 ,  B01L2400/0409 ,  B01L2400/0688 ,  B01L2400/084 ,  G01N35/00069 ,  G01N2035/1032

Abstract: A medical system for determining an analyte quantity in a blood sample via a cartridge that spins around a rotational axis. The cartridge may include: a separation chamber that separates blood plasma from the sample; a processing chamber containing a reagent with a specific binding partner which binds to the analyte to form an analyte specific binding partner complex; a first valve structure connecting the separation chamber to the processing chamber; a measurement structure to measure the quantity of the analyte, wherein the measurement structure includes a chromatographic membrane with an immobilized binding partner for direct or indirect binding of the analyte or the analyte specific binding partner complex, and an absorbent structure that is nearer to the axis than the membrane; a second valve structure connecting the processing chamber to the measurement structure; and a fluid chamber filled with a washing buffer and fluidically connected to the measurement structure.

公开(公告)号：US20160145281A1

公开(公告)日：2016-05-26

申请号：US14867074

申请日：2015-09-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Robert Cysewski ,  Luisa de Cola ,  Jesus Miguel Fernandez Hernandez ,  Hans-Peter Josel ,  Eloisa Lopez-Calle ,  Toralf Zarnt

IPC: C07F15/00 ,  G01N21/76 ,  G01N33/58

CPC classification number: C07F15/0033 ,  G01N21/76 ,  G01N33/533 ,  G01N33/582 ,  G01N2458/30

Abstract: Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in the electrochemiluminescence based detection of an analyte.